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Abstract Eliciting antibodies that are cross reactive with surface proteins of diverse strains of
highly mutable pathogens (e.g., HIV, influenza) could be key for developing effective universal
vaccines. Mutations in the framework regions of such broadly neutralizing antibodies (bnAbs) have
been reported to play a role in determining their properties. We used molecular dynamics
simulations and models of affinity maturation to study specific bnAbs against HIV. Our results
suggest that there are different classes of evolutionary lineages for the bnAbs. If germline B cells
that initiate affinity maturation have high affinity for the conserved residues of the targeted
epitope, framework mutations increase antibody rigidity as affinity maturation progresses to evolve
bnAbs. If the germline B cells exhibit weak/moderate affinity for conserved residues, an initial
increase in flexibility via framework mutations may be required for the evolution of bnAbs.
Subsequent mutations that increase rigidity result in highly potent bnAbs. Implications of our
results for immunogen design are discussed.
DOI: https://doi.org/10.7554/eLife.33038.001
Introduction
The HIV/AIDS epidemic affects more than 37 million individuals worldwide, and there were 2 million
new infections in 2014 (Deeks et al., 2015). The introduction of antiretroviral drugs in the 1990s has
made HIV infection a manageable condition, but less than half of the persons diagnosed with HIV
remain in care in the United States. In sub-Saharan Africa, the epicenter of the disease, this problem
is far more acute. Vaccination is a way to confront this challenge and eradicate the disease. One
major obstacle to developing a universal vaccine is the high mutability of HIV (Korber et al., 2001).
In order to prevent new infections, the vaccine-induced immune response must protect against a
great diversity of circulating HIV strains. Antibodies (Abs) that can neutralize a broad diversity of HIV
strains, known as broadly neutralizing antibodies (bnAbs), are of great interest in this regard because
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they have shown potential to both prevent new infection in animal models and to control existing
infection for some duration in both human and animal models (Barouch et al., 2013; Klein et al.,
2012; Mascola et al., 2000; Moldt et al., 2012; Lu et al., 2016).
BnAbs naturally evolve in only a subset of HIV-infected patients, and usually in low titers after sev-
eral years of infection. The isolation of bnAbs from patients provides proof that the human immune
system can evolve such antibodies. Past attempts at eliciting them by vaccination have failed
(Kong and Sattentau, 2012; McCoy and Weiss, 2013). Many efforts are currently underway to
design immunogens and vaccination strategies that can induce bnAbs. Despite significant progress
(Shaffer et al., 2016; Wang et al., 2015; Escolano et al., 2016; Steichen et al., 2016;
Bonsignori et al., 2016), a vaccination protocol that can efficiently induce bnAbs in non-human pri-
mates or humans is not available.
The key process in the development of Abs is a Darwinian evolutionary process known as affinity
maturation (Shlomchik and Weisel, 2012; Victora and Nussenzweig, 2012). A B cell is activated
upon binding of its B cell receptor (BCR) to a part of the proteins (epitope) that constitutes the anti-
gen (e.g., spikes on the surface of viruses). Activated B cells can seed structures called germinal cen-
ters (GCs) in lymph nodes where affinity maturation occurs. During affinity maturation (AM) B cells
proliferate, and upon induction of the activation-induced cytidine deaminase (AID) gene, mutations
are introduced in the receptor at a high rate (somatic hypermutation). The B cells with mutated
BCRs then interact with the antigen displayed on the surface of Follicular Dendritic Cells (FDCs). The
B cells undergo selection to favor those with receptors that bind more strongly to the target epi-
tope. Upon immunization with a single antigen, as cycles of diversification and selection ensue in the
GC, antibodies with increasingly higher affinity for the antigen are produced (Eisen and Siskind,
1964).
For an HIV vaccine to produce bnAbs, immunization with a single strain of antigen will likely not
suffice as it would lead AM to produce strain-specific antibodies. Immunization with multiple variant
antigens that have the same amino acid sequence at conserved positions on the viral spike proteins,
but diverse amino acids at the surrounding positions, are likely to be required. An example set of
conserved residues is the CD4 binding site, which is a part of the epitopes targeted by certain
bnAbs. Recent studies have suggested that the variant antigens can act as conflicting selection
forces, which frustrate the Darwinian evolutionary process of AM under some conditions
(Shaffer et al., 2016; Wang et al., 2015). Under some circumstances, the importance of sequential
immunization with variant antigens for the induction of bnAbs has been shown (Wang et al., 2015;
Escolano et al., 2016; Steichen et al., 2016), and the possibility of designing optimal cocktails of
variant antigens has also been noted (Dosenovic et al., 2015; Shaffer et al., 2016).
BnAbs exhibit unusual structural features such as a high degree of somatic hypermutation (includ-
ing insertions and deletions) in the antigen binding regions known as the complementarity determin-
ing regions (CDRs), as well as changes in the surrounding framework regions (FWR) (Scheid et al.,
2009; Sok et al., 2013). Most efforts to understand the evolution of bnAbs have concentrated on
mutations in the CDRs. However, mutations in FWRs that are spatially separated from the antigen-
binding site may also affect binding properties. For example, Klein et al. showed that, for the bnAbs
they studied, the reversal of FWR mutations reduces breadth and potency. However, the FWR muta-
tions had no effect on non-broadly neutralizing antibodies (Klein et al., 2013). This finding implies
that FWR mutations can be important for the broadly neutralizing activity, and it has been proposed
that FWR mutations increase neutralizing breadth by providing the Ab with greater conformational
flexibility (Scheid et al., 2011; Klein et al., 2013). A subsequent study of the 4E10 bnAb also found
a high degree of plasticity in the mature antibody (Finton et al., 2014).
The implications of these studies contradict the established paradigm of antibody maturation,
which suggests that antibodies progressively become more rigid as AM ensues (Schmidt et al.,
2013; Eisen and Chakraborty, 2010; Foote and Milstein, 1994; Wedemayer et al., 1997;
Thorpe and Brooks, 2007). Since bnAbs evolve upon undergoing AM induced by multiple variant
antigens, different selection forces may be at play.
A recent study on a class of enzymes showed that adaptation to different ligands in a PDZ
domain preferentially occurred not only through mutations in the ligand-binding site, but rather
through a collection of distant mutations (Raman et al., 2016). These mutations worked allosterically
to enable multiple conformational states, therefore allowing binding to a diversity of ligands during
adaptation. This finding, and those reported by Nussenzweig and co-workers (Scheid et al., 2011;
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Klein et al., 2013), led us to hypothesize that mutations in the framework region (FWR) of BCRs
could potentially affect the conformational states of the antigen binding region and allow BCRs to
bind to a broad range of variant antigens present during AM induced by natural infection or vaccina-
tion. This may, in turn, enable B cells to better negotiate the conflicting selection forces represented
by the variant antigens and thus facilitate the evolution of bnAbs.
To explore this hypothesis, we used molecular dynamics (MD) simulations to quantify the struc-
tural flexibility of antibodies obtained at different stages of AM in three bnAb lineages. These stud-
ies were augmented by a simplified computational model of AM in the presence of multiple variant
antigens that simulated the effect of mutations in both the CDR and the FWR to provide insight on
the evolution of flexibility and its influence on breadth.
Our results suggest that distinct evolutionary pathways are followed during the evolution of
breadth and potency in bnAbs, and we provide mechanistic insights into the underlying reasons. If
the binding affinity of the germline BCR to the conserved residues shared by the variant antigens is
high, the traditional paradigm where the antibodies become progressively more rigid as AM pro-
gresses is predicted. If this is not the case, FWR mutations that increase flexibility are favored. Addi-
tional complexities are predicted as breadth and potency evolve. From the standpoint of designing
vaccination protocols, our results imply that, if model antigens can prime germline B cells whose
BCRs bind strongly to the shared conserved residues of the boosting variant antigens, inducing FWR
mutations that influence receptor flexibility is not essential for the evolution of bnAbs. This is signifi-
cant as it simplifies the task of immunogen design.
Results
MD simulations of different bnAb lineages show varying effects of
framework mutations
Description of the MD simulations
We used atomistically detailed molecular dynamics (MD) simulations to study how flexibility evolved
in three different bnAb lineages (see Table 1): bnAbs 3BNC60 and CH103 bind to the CD4 binding
site on the HIV gp120 protein, and bnAb PGT121 binds primarily to glycans near the V3 chain of
gp120. We chose these specific lineages because of the availability of high-resolution crystal struc-
tures of germline, intermediate, and mature antibodies.
Table 1. Structures of the broadly neutralizing antibodies investigated in this study.
For each lineage, three structures are considered: the matured Ab, an intermediate maturity Ab, and
an inferred unmutated germline structure (the exact sequence of the germline B cell that seeds a GC
is difficult to know as some junctional diversity could be introduced prior to the GC reaction). Resolu-
tion of the structures is indicated after the PDB ID. Only the variable chains of the antibodies were
simulated (see Materials and methods).
Lineage Maturity Pdb id (A˚)
3BNC60 Matured 3RPI (Scheid et al., 2011) (2.64)
Germline 5F7E (Scharf et al., 2016) (1.90)
P61A reversal* 4GW4 (Klein et al., 2013) (2.65)
CH103 Matured 4JAN (Fera et al., 2014) (3.15)
UCA 4QHK (Fera et al., 2014) (3.49)
Chimera† 4QHL (Fera et al., 2014) (3.15)
PGT121 Matured 4FQ1 (Mouquet et al., 2012) (3.0)
Germline 4FQQ (Mouquet et al., 2012) (2.4)
Chimera‡ 5CEZ (Garces et al., 2015) (3.0)
*Single mutation reverted from bnAb;
†Intermediate HC with the LC from the unmutated common ancestor (UCA);
‡Intermediate HC 3 hr with mature LC 109L.
DOI: https://doi.org/10.7554/eLife.33038.002
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We generated five 100ns trajectories for each structure, starting from different initial conditions
(velocities; see Materials and methods). The root mean square distances (RMSD) from the initial
structures are shown in Figure 1—figure supplement 1. The RMSD time series for each of the five
trajectories are concatenated to show that trajectory differences are significant, thus indicating that
the trajectories are not correlated and each is meaningful. With the exception of the heavy chain
(HC) of the mature 3BNC60, the RMSD are under about 1.5 A˚, indicating that the structures are sta-
ble in the simulation. Examination of the 3BNC60 trajectory showed local b-sheet instability near res-
idue P61 which leads to partial unfolding of a beta hairpin in simulation 5 (see Figure 1—figure
supplement 1A, and also Figures 1A and 2A, discussed below). This result is consistent (see below)
with experiments (Klein et al., 2013). The RMSD graphs also provide a qualitative measure of anti-
body flexibility. For example, in the 3BNC60 lineage, the HC shows progressively higher RMSD
going from the germline (GL) to the mature structure. The reverse is observed for the CH103 HC,
although the differences appear smaller than in the 3BNC60 case. The PGT121 lineage exhibits
more complexity that is described below in quantitative terms.
To assess the flexibility quantitatively as a function of residue number, the structures obtained
from the all-atom simulations were coarse-grained to a representation of one bead per residue (see
Materials and methods) and RMS positional fluctuations from the mean bead position were com-
puted for each bead. More flexible molecules are characterized by larger RMS fluctuations. Further,
the standard deviation in the RMSF plots allows one to distinguish between antibody regions that
are flexible but stably folded (small Std. Dev.) and antibody regions that are either partially unfolded
or have significant conformational heterogeneity across the simulations (high Std. Dev). This coarse-
Figure 1. RMSF of the CG residue model of the heavy chains (A–C) and the light chains (D–F). (A,D) 3BNC60 lineage; (B,E) CH103 lineage; (C,F)
PGT121 lineage. In order to compare the three lineages, all sequences are multiply aligned. This procedure creates gaps in the traces corresponding to
antibodies with shorter loops in the region; i.e., there are no actual missing residue coordinates. The dashed lines bound the region of one standard
deviation above and below the average trace. Bullets indicate mutations acquired during AM. The definitions of FWR and CDR regions are taken from
(Scheid et al., 2011).
DOI: https://doi.org/10.7554/eLife.33038.003
The following figure supplement is available for figure 1:
Figure supplement 1. Root mean square distance between simulation and initial structures for the 3BNC60 lineage.
DOI: https://doi.org/10.7554/eLife.33038.004
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graining also allowed us to calculate the conformational entropy of the antibodies, which is a quanti-
tative thermodynamic measure of their overall flexibility. Toward this end, we used standard quasi-
harmonic analysis which treats each bond as a spring (see Materials and methods). Although it is
known that the conformational entropy from quasi-harmonic analysis typically overestimates the true
conformational entropy (see, e.g., [Tyka et al., 2007]), the relative differences between the struc-
tures studied are expected to be meaningful because of the overall structure similarity of antibodies
in the same lineage. More flexible molecules are characterized by a larger value of the conforma-
tional entropy.
Results of the MD simulations
The results shown in Figure 1A quantify the dramatic effect of the P61A reversal mutation in the
heavy chain of 3BNC60. Consistent with experiments, the presence of proline in the mature antibody
disrupts the secondary structure of the b-sheet connecting the CDR2 and FWR3 regions, resulting in
partial unfolding of the region (Klein et al., 2013). The magnitude of the fluctuations in the CDR
regions is illustrated qualitatively in Figure 2A by overlaying multiple CDR conformations. The fluctu-
ations are highest in the region surrounding the P61 residue. The high fluctuations propagate to
other regions (e.g. FWR1/CDR1 and FWR3) because of geometric (but not sequence) proximity (Fig-
ure 1). The large RMS fluctuations indicate a more flexible structure, and are thus consistent with
the observation that the melting temperature for the P61A reverted 3BNC60 mature antibody was
5K lower than that for the mature bnAb (Klein et al., 2013). Although the P61A single reversal has a
dramatic effect on the dynamics of the Ab, it is clear from Figure 1A that other somatic mutations
also increase the flexibility of the 3BNC60 heavy chain relative to the germline structure. This is
made clear from the values of the calculated conformational entropy (Figure 3), where we observe a
progressive increase in the conformational entropy from the germline to intermediate to mature
antibody for the 3BNC60 lineage. The conformational entropy of the light chains of the 3BNC60 line-
age of antibodies show a modest decline (Figure 3). From these results we conclude that there was
a progressive increase in flexibility of the 3BNC60 lineage of antibodies as affinity maturation
progressed.
The evolution of flexibility of the heavy chains of the CH103 lineage is opposite to that of
3BNC60 (Figure 1B), since the antibodies become progressively stiffer as the lineage matures. This
Figure 2. MD simulation structures of antibodies. (A) Simulation structure of the mature 3BNC60 antibody. Antibody framework regions are shown in
orange, and the CDR regions are in purple. The conformational flexibility of the CDR regions of the heavy chain is illustrated by overlaying 24
conformations of the CDRs in 4ns intervals from each of the five trajectories. The P61 residue is shown in black; (B) simulation structure of the
intermediate PGT121 antibody. The structure is colored as in (A), except that the conformational flexibility is illustrated for the FWR region of the light
chain using 24 overlaid orange curves; (C) simulation structure of the mature CH103 antibody. Twenty-four gray curves are overlaid to illustrate the
relatively lower overall flexibility of this antibody.
DOI: https://doi.org/10.7554/eLife.33038.005
The following figure supplements are available for figure 2:
Figure supplement 1. Interactions between the CDR1 and FWR3 regions of the PGT121 light chain.
DOI: https://doi.org/10.7554/eLife.33038.006
Figure supplement 2. Structure of antibody 3BNC60 (Scheid et al., 2011).
DOI: https://doi.org/10.7554/eLife.33038.007
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is reflected in both the RMS fluctuations and the conformational entropy (Figure 1B and Figure 3A).
This result indicates that increased flexibility is not always required to achieve breadth, even for anti-
body lineages that target the same region (the CD4 binding site). In fact, (Fera et al., 2014) attri-
bute the breadth increase in the CH103 lineage to a reorientation of the LC relative to the HC,
which alleviates steric clashes with gp120 variants that have longer V5 loops. Furthermore, the varia-
tion in flexibility that we report for the CH103 lineage is consistent with earlier studies of non-
broadly neutralizing antibodies, which also showed a loss of flexibility during maturation
(Chong et al., 1999; Thorpe and Brooks, 2007; Wong et al., 2011), and with the traditional para-
digm of affinity maturation (Foote and Milstein, 1994; Wedemayer et al., 1997). The light chains
of the CH103 also show a loss of flexibility upon maturation, although this change is more modest.
For the PGT121 lineage, our MD simulation results exhibit greater complexity. For the heavy
chains of this lineage, flexibility changes are observed in the CDR3 region (Figure 1C). In this anti-
body, CDR3 has a 11 residue insertion relative to the 3BNC60 and CH103 lineages, and is involved
in binding to gp120 glycans (Garces et al., 2015). The CDR3 heavy chain compared to the germline
loses flexibility with maturation, again consistent with the traditional paradigm. However, our simula-
tions did not show statistically significant flexibility differences outside of the CDR3 (as indicated by
95% confidence limits associated with 2  Std. Dev.) suggesting that the overall flexibility reduction
of PGT121 HC upon maturation is rather modest. Differences in the conformational entropy for this
antibody (Figure 3) are consistent with this observation. Although the flexibility differences for the
HC of the PGT121 lineage are modest, the variation in flexibility for the LC is significant. We studied
three structures – the mature PGT121 antibody, the germline structure, and an antibody construct in
which a lightly-mutated heavy chain (3 hr with 11% amino acid mutations, [Sok et al., 2013]) was
paired with a heavily-mutated light chain (109L with 34% mutations, [Sok et al., 2013]). Since the
109L LC is heavily mutated (i.e., like the mature PGT121 LC, which is 28% mutated [Sok et al.,
2013]), the 109L LC can be considered another variant of the mature light chain. Since it is paired
with a lightly mutated heavy chain, we consider the 3 hr/109L antibody structure to be representa-
tive of an intermediate stage of PGT121 evolution. While the mature variant is less flexible than the
germline in the regions FWR3-FWR4, the intermediate construct has high flexibility, particularly in
the framework regions (see Figure 1F and Figure 2B). This result underscores that the dramatic flex-
ibility increase observed for the 3BNC60 HC above is not an isolated occurrence. Specifically, both
chains of the 3H109L PGT121 intermediate have higher entropies than the corresponding germline
and mature structures, with the increase being more pronounced for the light chain (Figure 3), on
which we focus below.
To understand the physical basis for the markedly increased fluctuations in the 3 hr/109L interme-
diate, we examined the simulated structures and the sequences of the mature PGT121 and of the
Figure 3. Evolution of flexibility differs for our three bnAb lineages. Absolute classical quasi-harmonic entropy for the CG antibody model of the heavy
(A) and light (B) chains, shown as the contribution to the absolute free energy ( TS). The absolute entropy magnitude tends to be larger for the heavy
chains than for the light chains because they have more amino acids (e.g. 123 aa. for 3BNC60 HC vs. 98 aa. for 3BNC60 LC).
DOI: https://doi.org/10.7554/eLife.33038.008
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intermediate 3 hr/109L. In the PGT121 light chain, the FWR3 region near residue 68 is well ordered,
and interacts with the CDR1 region near residue S27 (Figure 2—figure supplement 1). Hydrogen
bonds are formed between S27 (both, side chain and backbone oxygens) and G68 (backbone
amide). In the 109L LC the serine is an alanine, and the stabilizing hydrogen bonds do not form,
which allows the FWR3 region to unfold locally near the three residue insertion 66(a)P-66(b)D-66(c)I.
In the mature PGT121 light chain, this insertion is mutated to 66(a)D-66(b)S-66(c)P (Figure 2—figure
supplement 1), and in conjunction with A27S, results in a stable conformation. However, it is possi-
ble that this conformation is only weakly stable, such that minor changes in the adjacent structure
(such as the S27A mutation in the CDR1) could cause unfolding. Therefore, the stability of FWR3 in
the intermediate 109L LC appears to depend, at least in part, on the sequence identity of CDR1,
which might seem surprising because the framework regions are thought to provide a relatively rigid
scaffold to which variable and flexible CDR regions are attached. Other sequence differences
between the mature LC and 109L in or near the insertion region could also be significant, such as
S65T or S66(c)I. However, examination of the trajectory did not implicate these residues in the insta-
bility directly, because they are oriented away from the CDR1 loop. These results suggest that the
complete explanation for the increased flexibility is quite complicated.
Overall, our results demonstrate that flexibility throughout the antibody can be changed signifi-
cantly by mutations in both the FWR and CDR regions, and, more generally, that affinity maturation
in bnAbs does not follow the rigidification paradigm in all cases.
A model of AM suggests that the binding affinity of the germline BCR
to the conserved regions of the epitope determines the role of
framework mutations on bnAb evolution
Our analyses of MD simulation results clearly indicate significant ‘exceptions’ to the paradigm of
antibody rigidification during affinity maturation. For the 3BNC60 lineage, flexibility progressively
increased, while the opposite is true for the CH103 lineage. For the PGT121 lineage, our results indi-
cate that the intermediate is more flexible than either the mature or germline antibodies, so that this
is an example of a more complex maturation trajectory. The germline for the CH103 lineage bound
strongly to the CD4 binding site of the founder HIV envelope glycoprotein (Liao et al., 2013). Con-
versely, ancestors of 3BNC60 show lower potency and breadth of neutralization (Scheid et al.,
2011; Klein et al., 2013). Therefore, although the founder viral strain for the patient from whom
3BNC60 was harvested was not available, this result suggests that the 3BNC60 ancestors bind
weakly to the CD4 binding site of the epitope that induced bnAb evolution. In general, it is not likely
that a naive germline B cell will have a strong affinity for the shared conserved residues. Thus, we
hypothesized that the traditional paradigm of reduced flexibility with maturation applies when the
germline BCR binds strongly to the conserved shared residues of the variant antigens that induce
the evolution of bnAbs. More complex evolution of flexibility can result when this is not the case, as
we found for the 3BNC60 and PGT121 lineages. To explore this hypothesis in light of processes that
occur during AM in the presence of variant antigens, we developed a simplified model of AM.
Description of the affinity maturation model
Past studies analyzing the evolution of bnAbs in infected persons show that often diversification of
viral strains precedes the development of bnAbs (Liao et al., 2013; Doria-Rose et al., 2014;
Bhiman et al., 2015). Thus, we studied AM induced by a cocktail of multiple variant antigens. Our
computational model of affinity maturation of B cells includes somatic hypermutation (SHM) in the
CDR as well as in the FWR. The purpose of our computational model is not the quantitative repro-
duction of existing experiments or our MD simulation results, but rather to provide mechanistic
insights into how mutations in the CDR and FWR regions change the flexibility of Ab structure to
influence the development of breadth and potency. As in recent models of the mutation and selec-
tion phenomena that occur during AM induced by multiple variant antigens, which predicted phe-
nomena that were experimentally validated (Wang et al., 2015), our model for AM does not
explicitly consider the motion of B cells in space or the atomistically detailed structure of BCRs and
antigens. The model is conceptually similar to the one described by (Wang et al., 2015) and
(Shaffer et al., 2016), but we adopt a different approach to modeling the BCRs, the variant anti-
gens, and their interactions with each other. The present approach explicitly considers the flexibility
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of the antibody structures in determining the free energy of interactions between BCRs and anti-
gens. We first describe how the binding free energy is estimated, and then show how the various
steps of AM are computed (further details are provided in the Materials and methods).
The variant antigens have a certain fraction l of their amino acid sequence that is the same. This
fraction represents the shared conserved residues of the targeted epitope; (1- l) is the fraction of
amino acids that differ. Each B cell is characterized by its binding energy Ec to the shared conserved
region, and its binding energy Evi to the variable part of each antigen i. Lower (i.e., more negative)
binding energies indicate stronger binding. Further, the flexibility of the BCR can play an important
role in determining the entropy loss on binding. For more rigid BCR structures, there is a smaller
loss of entropy upon binding; for more flexible BCRs, the binding free energy is less favorable (for
the same binding energy) because of the greater entropy loss. However, since more flexible struc-
tures can bind to more diverse antigen variants, increased flexibility can contribute favorably to the
binding energy. For simplicity, we characterize the structural flexibility of a BCR by a single parame-
ter Q, which take values between 0 and 1; Q = 0 and Q = 1 correspond to a highly flexible and a
highly rigid structure, respectively. Given the analysis above, we introduce an approximate model
for the binding free energy, for a BCR characterized by Q, Ec and Evi (defined above) with antigen
variant, i, it is defined as:
E¼Q lEcþ 1 lð ÞEvið Þþ 1 Qð ÞE0 (1a)
¼QEwþ 1 Qð ÞE0; (1b)
E becomes more favorable as mutations are acquired that increase the binding energy of the
BCR to the residues of the antigen. The first term in Equation 1(b), QEw, includes an approximation
to the entropy contribution to the free energy, based on the reasonable assumption that the effect
of flexibility can be captured by scaling down the energy Ew. As the BCR becomes more flexible
(smaller Q), because of the greater entropy loss associated with binding, the net binding free energy
(QEw) is smaller for the same value of Ew. E0 corresponds to a moderate favorable ‘generic’ binding
free energy to all variant antigens accessible through conformational plasticity. The second term in
Equation 1(b) plays an increasingly important role for flexible BCR structures (smaller values of Q).
For simplicity, we assume that mutations in the CDR affect the binding energy (Ec or Evi, depending
on their location) and that mutations in the FWR only affect the rigidity of the BCR (Q) and not the
binding energy. The model could be refined by taking into account different flexibilities of the epito-
pes on variant antigens. As there is no way to know the distribution of epitope flexibilities, we have
instead studied the influence of varying the value of E0.
More negative binding free energies correspond to stronger affinities. The absolute value of the
binding free energy is arbitrary as free energies are determined only up to an additive constant. We
assume that a binding free energy of zero is the minimum required for antigen binding (for example
only B cells that bind to antigen with a more favorable binding free energy than zero can seed a Ger-
minal Center (GC)). The binding free energies in our model are expressed in units of kBT (see text
following Equation 4 in Materials and methods).
We simulate the processes that occur during AM using a stochastic model, as is appropriate for
an evolutionary process. The set of rules that define AM are derived from experimental studies of
affinity maturation with a single antigen (Allen et al., 2007; Berek and Milstein, 1987; Tas et al.,
2016; Victora and Nussenzweig, 2012), and these serve as instructions that are executed by the
computer. The following steps are executed for the situation where there exists a number of variant
antigens displayed on the Follicular Dendritic Cells (FDCs) in the GC.
Seeding of a GC and somatic hypermutation (SHM)
We select a few founder B cells that bind to one of the variant antigens with a binding free energy
above a threshold (defined above) to seed a GC. The founder B cells expand reaching a population
of 1,536 cells. Then, the AID gene turns on and mutations are introduced with a probability deter-
mined by experiments: each B cell of the dark zone divides twice per GC cycle (four divisions per
day) (Zhang and Shakhnovich, 2010) and a mutation occurs with a probability of 0.20 per sequence
per division (Berek and Milstein, 1987). The mutations affect both the CDR and the FWR. Although
the FWR constitutes over two thirds of the variable domain by sequence, mutational hotspots have
mostly been found in the CDR (Neuberger and Milstein, 1995; Tomlinson et al., 1996;
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Wagner and Neuberger, 1996). Thus, we assume that the probability that a mutation occurs is
higher in the CDR (pCDR) than in the framework (pFWR). The precise values of the parameters used
are provided in Supplementary file 1 and 2.
CDR mutations
CDR mutations can cause a B cell to undergo apoptosis (for example, by making the BCR unable to
fold), be silent (e.g., synonymous mutation), or modify the binding energy. The probability that a
CDR mutation will follow one of these paths is governed by probabilities obtained from experiments
(Berek and Milstein, 1987). Apoptosis occurs half of the time, 30% of mutations are silent, and 20%
are binding energy-affecting mutations (Zhang and Shakhnovich, 2010). Experimental studies of
protein-protein interactions indicate that binding energy-affecting mutations are more likely to be
deleterious than advantageous (Moal and Ferna´ndez-Recio, 2012). Therefore, in our model, the
change in binding energy is sampled from a shifted log-normal distribution whose parameters are
chosen to approximate the observed empirical distribution of changes in binding energies upon
mutation. In our model, the CDR mutations change Ec or Evi, depending on their location, but do
not affect flexibility (Q).
FWR mutations
In the case of a mutation in the FWR, we assume that the likelihood of undergoing apoptosis is very
high (80%) to account for the role of the FWR in maintaining the structural integrity of antibodies.
Non-lethal mutation yields a change in the flexibility of the structure, which is represented by a
change in the rigidity parameter Q that is randomly sampled from a Gaussian distribution. We allow
Q to vary between a state of maximum rigidity (Q = 1) and a state of high flexibility (Q = 0.1). If a
mutation would increase Q above one or decrease it below 0.1, we simply set Q equal to the bound-
ary value of 1 or 0.1, respectively. Because FWR regions tend to be farther from the binding inter-
face than CDR regions, we assume that FWR mutations do not directly affect binding energy (Ec or
Ev); their effects are introduced indirectly through changes in Q.
Selection
After SHM, the mutated B cells then migrate to the light zone of the GC, where selection takes place
through competition for binding to antigens displayed on FDCs and for receiving T-cell help. We do
not model the spatial migration step explicitly, but rather selection occurs after the rounds of divi-
sion and somatic hypermutation in the dark zone. As our goal is to explore how the qualitative
nature of the evolutionary paths followed by B cells in the GC depend upon the strength of binding
of the germline B cells to the conserved residues of the epitope, treating migration explicitly is not
necessary.
In the GC, B cells interact with antigen displayed on FDCs. B cells with receptors that bind more
strongly to the antigen will likely internalize more antigen. They are thus more likely to display larger
numbers of antigen-derived peptides bound to MHC Class II molecules on their surface. The B cells
that internalize antigen and display peptide-MHC molecules on their surface compete with each
other for the limited number of T helper cells in the GC. If there is a productive interaction of pep-
tide-MHC molecules on B cells undergoing selection and the T cell receptor on the surface of T
helper cells, the B cell receives a survival signal, and if it does not, apoptosis results (Foy et al.,
1994; Crotty, 2015). B cells that display more peptide-MHC molecules on their surface are more
likely to receive this survival signal.
We model the two-step selection process noted above as follows. First, each B cell successfully
internalizes the antigen it encounters with a probability that grows with the binding free energy and
then saturates, following a Langmuir form (see Equation 4 in Materials and methods). B cells that
successfully internalize antigen can then go on to the second step, while the others die automati-
cally. The B cells that internalize antigen are ranked according to their binding free energy, which is
expected to correlate with the concentration of pMHC that they display to T cells, and only the best
performers are selected (see Supplementary file 1 and 2 for details on parameter values).
In the presence of multiple antigen variants present on FDCs, a B cell could interact with and
internalize several variants at a time or just one variant. However, there is no experimental data to
describe how heterogeneously different antigens are distributed on the surface of FDCs at a given
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time. It was shown previously that, if B cells interact with multiple variants of the antigen in every
cycle, bnAbs are less likely to evolve (Wang et al., 2015; Shaffer et al., 2016). Therefore, in our
model we assume that a B cell encounters only one antigen variant on FDCs at a time; a different
choice would lower the probability of bnAb evolution. The encountered antigen variant is chosen
randomly with a uniform probability for each B cell during each round of selection.
Recycling, exit for differentiation, and termination of the GC reaction
Most (70%) B cells that are positively selected are recycled for further rounds of mutation-selection
while a few randomly selected B cells exit the GC to mimic the differentiation into memory and anti-
body-producing plasma cells (Oprea and Perelson, 1997). The GC reaction comes to an end in
three possible circumstances: 1] All the B cells die, thus extinguishing the GC. 2] If the number of B
cells in the GC exceeds 1,536 cells; this is a proxy for the antigen being consumed by the B cells 3]
When the number of cycles, or time, exceeds a maximum number (250 cycles, or » 125 days assum-
ing two cycles per day; see Supplementary file 1 and 2 for full parameter values), which is a proxy
for the antigen having decayed or loss of antigen from the GC.
Although the model that we simulate lacks structural detail, it reproduces experimentally
observed order-of-magnitude increases in the binding affinity during AM induced by a single antigen
(see Materials and methods and Figure 4—figure supplement 1).
Simulated AM trajectories
For each simulated AM trajectory in the GC, we record the total number of B cells over time as well
as the number of acquired energy-affecting CDR mutations and rigidity-affecting FWR mutations.
Due to the stochastic nature of B cell evolution during affinity maturation, we carried out 104 simula-
tions for each set of conditions studied, and combined the results to obtain meaningful statistics.
Our results thus reflect the probability with which certain types of evolutionary patterns would be
observed for each set of conditions that we studied. Because mutation probabilities are less than
unity, cell division can generate cells with identical values for binding energies and rigidity. Thus, the
GC contains sets, also called clones, of these functionally identical B cells. We analyze the properties
of the clone with the largest number of cells at the end of the AM trajectory, and consider this to be
representative of the properties of most of the antibodies generated. We also trace the evolutionary
trajectories of these clones to determine the history of mutations in the CDR and FWR regions that
shaped these final properties. To analyze the antibody breadth, we compute the binding free energy
of this largest clone to a panel of 100 antigens different from those against which the antibody
matured. For this purpose, we take the overlap parameter l and the binding strength with the con-
served region to be the same as in the simulations of affinity maturation, but the binding strength
with the variable region is randomly selected for each new antigen in the panel (Materials and meth-
ods). As a proxy for breadth, we compute the median binding free energy with panel antigens of
each antibody over the maturation pathway . This allows us to track how breadth evolves during the
course of affinity maturation. The higher the magnitude of the median binding free energy the
greater the cross-reactivity of the Abs to variant antigens.
The results described in the main text have been carried out with ten variant antigens that share
90% sequence identity (l = 0.9), and three B cells seeding the GC. The precise number of antigens
and the value of l used in the simulation are not important for the qualitative results that we present
(for example, see Materials and methods and Figure 4—figure supplement 2 where results with
five antigens are shown). Similarly, increasing the number of seeding B cells to seven did not affect
our results.
Results of the affinity maturation model
To explore the hypothesis suggested by our MD simulation results, we considered two classes of
activated germline B cells that seed the GC upon immunization with a cocktail of variant antigens: 1)
those with a high favorable value of the binding energy to the shared conserved region of the anti-
gens, Ec (such as those that have a long finger-like structure that binds to the CD4 binding site in
the VRC01 family of antibodies); and 2) those with a weak/moderate binding energy to the shared
conserved regions, which are expected to be more common upon natural infection, since most naı¨ve
B cells are unlikely to have strong interactions with the conserved residues prior to affinity
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maturation. The Abs start with a high value of the rigidity parameter, Q = 0.8. The exact initial value
of Q had little qualitative effect on the outcome (data not shown).
Our results show strikingly different Ab evolution patterns and outcomes depending on the initial
value of Ec (Figure 4). When the germline B cells bind to the conserved residues with relatively high
affinity (e.g., Ec »  4), B cells evolve CDR and FWR mutations that strengthen the binding energy
(Ec) to the shared conserved residues and reduce the flexibility of the antibody (increase Q); if the
initial Q is already high, the increase may be relatively small. This is consistent with our MD simula-
tion results for the CH103 lineage (and the traditional paradigm). The resulting antibodies are both
broad and potent as reflected by the median binding free energy to the panel of antigens and the
absolute magnitude of Ec (Figure 4). Thus, these antibodies acquire breadth and potency by focus-
ing their interactions with the variant antigens on the shared conserved residues (more favorable Ec).
This is the situation with the class of antibodies that acquire breadth and potency by focusing inter-
actions with the CD4 binding site.
In the case where the binding energy of the germline B cell to the shared conserved residues is
weaker (taken to be Ec = 0), we find that B cells typically need to acquire FWR mutations that
increase their flexibility in order to be able to be positively selected in the presence of multiple vari-
ant antigens (Figure 4). This is made evident by the fact that in simulations where changes to flexibil-
ity are disallowed, GC reactions are 35% less likely to complete successfully because all the B cells
undergo apoptosis as AM ensues (data not shown). Akin to enzymes in a changing environment of
substrates (Raman et al., 2016) discussed earlier, the FWR mutations enable the B cells to bind
loosely to the diverse variant antigens that act as the selection forces during affinity maturation.
Since the value of Ec during the early stages of affinity maturation is not high, one way for the B cells
to bind sufficiently strongly to diverse variant antigens and be positively selected is by evolving FWR
mutations that increase conformational flexibility. Upon becoming more flexible and thus surviving
selection against the variant antigens, in subsequent rounds of mutation and selection, the B cells
can start to acquire CDR mutations that increase the binding energy to the conserved residues, thus
acquiring breadth. Most bnAbs harvested at this stage of evolution will exhibit high breadth and rel-
atively low potency because the free energy of binding to each variant antigen is not very high. This
is because the flexibility of the BCR/antibody implies that a high entropic penalty has to be paid
upon binding to the antigens (also see Equation 1 in the limit of small Q). In some cases, however,
the flexible bnAbs can also be highly potent. This is because, as our calculations show, some flexible
bnAbs that are produced at this stage of AM can develop strong interactions with the conserved
residues (Ec » –11). This may be the case for the 3BNC60 antibody, which was isolated from patients
with the specific selection criteria of high breadth and potency. As our MD simulation results show,
for this lineage, flexibility progressively increases with maturity; 3BNC60 exhibits high breadth, with
the potency expected to be comparable to that of CH103. Although we could not find specific com-
parative data for 3BNC60, another 3B class of bnAb, 3BNC117, is slightly more potent than CH103
(Chuang et al., 2013; Eroshkin et al., 2014). Indirect comparisons based on available data
(Scheid et al., 2011; Chuang et al., 2013) suggest that 3BNC55, another bnAb with the P61 FWR
mutation is less potent than CH103. This may be because it has not yet acquired the mutations
required for strong interactions with the conserved residues, and our calculations (Figure 4) suggest
that its flexibility makes 3BNC55 less potent.
Figure 4A shows that, in the case where germline B cells have a weak binding energy Ec, if the
evolutionary trajectories progress beyond a reasonably favorable value of Ec (which our simulations
show to be roughly equal to E0), then framework mutations that make the structure more rigid are
acquired much like the case where germline B cells exhibit a stronger Ec. Thus, the antibodies
become more potent because they do not have to lose conformational entropy upon binding (see
also Equation 1). Our results show that for the cases where the germline B cells have a low binding
energy to the conserved residues, the median binding free energy of the antibodies for the panel of
antigens exhibits a broad pattern at generation 400 (Figure 4B). Analyses of our results demonstrate
that the population that exhibits lower breadth (median binding free energy) and lower final values
of Ec is comprised of those antibodies that are more flexible, while those that continue to evolve
and become more rigid have a higher breadth and potency (Figure 4C). This rigidification, following
an initial increase in flexibility that enables the development of sufficiently strong interactions with
the conserved residues, would explain why the PGT121 bnAb is more potent than 3BNC60. Also,
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Figure 4. Antibody maturation proceeds along alternate routes that depend on the initial binding strength with the conserved region of the antigen.
Here we show statistics of the maturation pathways of the largest clones in our affinity maturation simulations. These figures therefore summarize
typical features of antibody maturation across many parallel and independent germinal center reactions. (A) Antibody lineages that initially bind
strongly with the conserved region of the antigen are likely to accumulate mutations that increase their binding strength and reduce flexibility. Starting
parameters are indicated with an arrow. In our simulations, mutations in the CDR affect binding energies directly, while mutations in the FWR affect
flexibility. Typical binding free energies with panel antigens, a proxy for breadth, strengthen steadily over the course of maturation (represented for
Figure 4 continued on next page
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these results are consistent with our MD simulations, which show that the intermediate is more flexi-
ble than both the germline or the mature antibodies.
For cases where the germline B cells exhibit a weak binding energy for the shared conserved resi-
dues of the antigens, we also observe some evolutionary trajectories where mutations quickly arise
in the CDR regions that increase the affinity to the conserved residues and this is followed by the
antibody structures evolving to become even more rigid. Such cases are less common.
The AM simulation results described above were obtained with a particular value of the “generic’’
binding energy E0 (nonspecific binding energy accessible to flexible antibodies; see Equation 1 a,b).
We have explored the effects of varying the value of this parameter on our results when the germline
B cell does not bind strongly to the conserved residues of the epitope (weak initial Ec). As Figure 4—
figure supplement 3 shows, shifting E0 to very strong or weak binding energies affects the pre-
ferred antibody maturation pathway. A significantly more favorable value of E0 than that used to
obtain the results in Figure 4 makes flexibility-increasing framework mutations more beneficial, and
thus drives antibody evolution more along 3BNC60-like trajectories (compare Figure 4—figure sup-
plement 3 with Figure 4B). In this case, antibodies begin to rigidify and become more like the
PGT121 lineage later in the maturation cycle, after mutations that make Ec (binding energy to the
conserved residues) very strong have been acquired. So, if E0 is stronger than what was used to
obtain the results in Figure 4, the qualitative behavior does not change, but the 3BNC60-like anti-
bodies are more likely to be observed for a greater duration of the affinity maturation cycle and are
likely to be more potent. If E0 is weaker than what was used to obtain the results in Figure 4, and
we use the same antigen concentration as before, most of the B cells die and the GC is likely to be
extinguished. This is because affinity maturation is frustrated when there are multiple variant anti-
gens and the initial Ec is weak, as has been described before (Wang et al., 2015; Shaffer et al.,
2016), and a path to relieving this frustration by evolving flexibility through FWR mutations is no lon-
ger available (because of weak E0). In this circumstance, if the antigen concentration is increased, we
find that the GCs are not extinguished with high probability, and more CH103-like maturation trajec-
tories are promoted (compare Figure 4—figure supplement 3 with Figure 4A). This is because
CDR mutations that improve binding with the conserved region (stronger Ec) become relatively
more beneficial early in the maturation process since E0 is weak and there is little benefit to evolving
FWR mutations that affect flexibility. Consistent with the points noted above, varying values of E0
also change the rate of acquiring CDR versus FWR mutations (Figure 6—figure supplement 1), with
stronger values of E0 promoting FWR mutations more than in Figure 6B and weaker values of E0 sup-
pressing FWR mutations.
Discussion
HIV is a highly mutable pathogen that continues to rage in many parts of the world. A promising
strategy for the development of a prophylactic vaccine against such pathogens is to design immuni-
zation protocols and immunogens that can induce antibodies (bnAbs) that can neutralize diverse cir-
culating mutant strains of the virus. BnAbs that evolve naturally in infected persons exhibit high
levels of CDR and FWR mutations. In some instances, FWR mutations are important for breadth
Figure 4 continued
generations 25, 150 and 400). (B) Antibodies that initially bind weakly with the conserved region typically become more flexible while increasing their
binding strength. Such antibodies may subsequently begin to rigidify as they mature. The typical binding free energies with panel antigens increase
slightly faster than in the strong conserved binding case above, but final binding free energies are not as strong. (C) The most potent antibodies at the
end of the maturation process (generation 400), measured by median binding energy with panel antigens, are those that are the least flexible.
DOI: https://doi.org/10.7554/eLife.33038.009
The following figure supplements are available for figure 4:
Figure supplement 1. Simulations of affinity maturation against a single antigen agree with experimental results.
DOI: https://doi.org/10.7554/eLife.33038.010
Figure supplement 2. Similar values of the overlap parameter lead to qualitatively similar results.
DOI: https://doi.org/10.7554/eLife.33038.011
Figure supplement 3. Shifting E0 affects the preferred antibody maturation pathway.
DOI: https://doi.org/10.7554/eLife.33038.012
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(Scheid et al., 2011) and, in at least one case, FWR mutations have been shown to increase antibody
flexibility (Scheid et al., 2011; Klein et al., 2013). The standard paradigm, based on the develop-
ment of strain-specific antibodies is that FWR mutations result in a more rigid antibody structure
(Schmidt et al., 2013; Eisen and Chakraborty, 2010; Foote and Milstein, 1994;
Wedemayer et al., 1997; Thorpe and Brooks, 2007). Since bnAbs develop by AM in the presence
of diverse mutant strains, we explored the hypothesis that FWR mutations increase the number of
accessible conformational states of the antigen binding region, thus enabling binding to the variant
antigens. This, in turn, may allow B cells to avoid frequent apoptosis due to the conflicting selection
forces represented by the variant antigens.
To test this hypothesis, we first performed atomistically detailed molecular dynamics simulations
of the structures of antibodies at three different time points during the maturation process for three
bnAb lineages (3BNC60, PGT121, and CH103). Only the 3BNC60 lineage, showed the continuous
increase in conformational flexibility previously reported (Scheid et al., 2011; Klein et al., 2013).
Structures in the CH103 lineage progressively became more rigid with maturation, consistent with
the standard paradigm. For PGT121, the germline and mature forms had similar levels of conforma-
tional rigidity, while an intermediate construct was more flexible, suggesting a more complex matu-
ration process.
To interpret these complex results in light of the evolutionary forces at play during the develop-
ment of bnAbs by AM, we developed and studied a simple computational model of AM driven by
multiple variant antigens. The essential findings from our simulations of affinity maturation are
depicted schematically in Figure 5, which illustrates how the three different cases studied here
evolve during AM; details are given with Equation (1) and the discussion of Figure 4 above. Specifi-
cally, Figure 5 shows the change in rigidity (Q) and the binding energy to conserved residues (Ec)as
a function of the value of Ec for the germline B cell. If Ec is sufficiently favorable (Ec  0), as in the
CH1 E103 case (Figure 5, orange), AM follows the classical path of increasing rigidity. If Ec is low
(Ec » 0), as is likely the case for 3BNC60 (green) and PGT121 (purple), rigidity initially decreases via
mutations in the FWR regions. The increase in flexibility allows the antibodies to bind a broader set
of antigens via conformational plasticity, with a relatively low but sufficiently strong affinity, to permit
them to survive until they acquire additional mutations that enhance Ec. That is, a more negative (or
stronger) binding free energy, E, can be acquired by increasing the magnitude of the second term in
Equation 1b at the expense of the first term. Then, further beneficial CDR mutations that strengthen
Ec can follow, thus making Ew more negative (stronger binding) for diverse variant antigens. This sce-
nario is consistent with both 3BNC60 and PGT121 cases. Most antibodies harvested at this stage of
AM will not be very potent because flexible antibodies lose more entropy upon binding, thus limit-
ing the value of E (green curve); however, some antibodies, such as 3BNC60, can also develop a
highly favorable value of Ec. At this stage in the AM process, rigidification can increase the antibody
potency further. This is observed in our simulations once Ec is sufficiently high that Ew <E0; conforma-
tional plasticity is now no longer required and the selection pressure will increase Q to enhance the
effect of the first term in Equation 1b. This phenomenon is consistent with the AM trajectories of
the PGT121 lineage (purple curve). The reason that PGT121 is more potent than 3BNC60 is likely
that it has proceeded further along the evolutionary trajectory and become more rigid.
In our model, we observe that the accumulation of mutations in the CDR and FWR regions differs
according to the maturation pathway (Figure 6). Antibodies that start with a relatively strong bind-
ing with the conserved region (CH103-like) accumulate mostly affinity-improving CDR mutations
while some FWR mutations contribute to rigidity (Figure 6A). In contrast, antibodies that start with
weaker binding to the conserved region (PGT121- and 3BNC60-like) more rapidly accumulate FWR
mutations that improve flexibility during the early stages of AM (Figure 6B). This is a prediction of
our model which is supported by experimental results from (Klein et al., 2013) where a phylogenetic
analysis of antibodies from the 3BNC60 lineage places two important FWR mutations near the root,
suggesting that they emerged early during the developmental process. Later CDR mutations then
contribute to increased binding affinity. Our predictions could be further tested by examining the
relative rates at which CDR and FWR mutations are acquired during the evolution of the CH103 and
PGT121 bnAb lineages.
The results have an important implication for the design of immunization strategies to induce
bnAbs. If germline B cells can be activated that bind sufficiently strongly to the shared conserved
residues of a target epitope of a class of bnAbs (e.g., the CD4 binding site), there is no need for the
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subsequent immunization with variant immunogens to induce FWR mutations that increase flexibility
of the BCRs as AM ensues. Thus, our results suggest that strategies that result in inducing such
germline B cells (Steichen et al., 2016; Escolano et al., 2016; Jardine et al., 2016; Jardine et al.,
2015; Jardine et al., 2013) would considerably simplify the design of boosting immunogens.
Our study represents a first step in understanding the complex synergies between FWR and CDR
mutations that are in play during the evolution of bnAbs. We hope our findings encourage others to
further study this fundamental problem at the intersection of immunology and evolutionary biology
with important implications for health. Several caveats in our study are worth noting as they provide
suggestions for such studies. We were able to study only three bnAb lineages because of the lack of
Figure 5. The three bnAb lineages we studied evolve through different paths that depend on the binding
strength of their germline to conserved epitopes. CH103 (in orange) has a strong starting binding energy for the
conserved residues, Ec. It follows the traditional evolution pathway and quickly rigidifies while enhancing its Ec.
PGT121 (in purple) and 3BNC60 (in green) have germlines with a weaker Ec. To survive selection during affinity
maturation with multiple different antigens, they follow the same pathway as some enzymes (Raman et al., 2016)
in changing environments: they first become m E1ore flexible which allows them to bind all antigens with limited
potency; later they acquire mutations that enhance Ec and increases their binding potency.
DOI: https://doi.org/10.7554/eLife.33038.013
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high resolution antibody structures at different points of maturation. Furthermore, we could only
study three time points in the evolutionary pathway of each lineage, and for PGT121, the structure
we studied is a chimeric construct and not a true intermediate. Our results suggest that complex
evolutionary trajectories are followed under different conditions, and structural analysis of various
bnAb lineages at multiple time points during their maturation pathway could further test our predic-
tions and reveal new phenomena. For example, studies that provide a finer temporal resolution dur-
ing AM could reveal additional types of evolutionary trajectories not described by our current
results. Iteration between such experiments and development of more refined models would further
elucidate the complex processes that occur when AM results in the development of bnAbs.
Materials and methods
Data and some analysis for molecular dynamics simulations are available in a GitHub repository
(Barton, 2018). A copy is archived at https://github.com/elifesciences-publications/paper-bnAb-
flexibility.
Molecular dynamics simulations
Antibody structures listed in Table 1 were downloaded from the PDB databank, and include both
the variable regions and the constant regions, which are connected by a single b-strand for each HC
and LC (Figure 2—figure supplement 2). To save simulation cost, the structures were truncated to
Figure 6. Accumulation of mutations in the CDR and framework regions varies according to the maturation pathway. (A) Antibodies that have a strong
initial binding energy for the conserved residues, Ec, tend to first accumulate CDR mutations. Later, these antibodies rigidify through framework
mutations. (B) Antibodies that have germlines with a weaker starting Ec are more likely to acquire early framework mutations to increase flexibility,
improving the odds of surviving selection during affinity maturation with multiple antigens. Note that nearly all lineages possess early framework
mutations, in contrast to the maturation trajectories in (A).
DOI: https://doi.org/10.7554/eLife.33038.014
The following figure supplement is available for figure 6:
Figure supplement 1. Shifting E0 affects the accumulation of mutations in the CDR and framework regions along the maturation pathway.
DOI: https://doi.org/10.7554/eLife.33038.015
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retain only the variable regions, since the constant regions do not contact the antigens. To truncate
all of the antibodies in equivalent locations, a multiple alignment of each chain was performed. The
truncation locations correspond to res. 120 and res. 98 for the heavy and light chains of 3BNC60,
respectively. Histidine protonation was performed by optimizing visually the hydrogen bonding pat-
terns for each histidine. The CHARMM36 energy function was used for the MD simulations. Each
structure was energy-minimized in vacuum using CHARMM (Brooks et al., 2009) with restraints on
the protein heavy atoms, and immersed in a cubic box of TIP3P water of sufficient size that the
smallest distance between the antibody and the box boundary was 11.5 A˚. Na  and Cl+ ions were
added to maintain system neutrality, while achieving an approximate salt concentration of 100 mM.
The final system sizes were between 40,000 and 51,000 atoms; variations were mainly due to differ-
ences in the CDR loop lengths (e.g., the PGT bnAb has the longest CDR3 region, and had about
51,000 atoms). MD simulations were performed using GPU hardware with the program ACEMD
(Harvey et al., 2009).
Each system was equilibrated for 2ns with restraints on the heavy atoms that were resolved in the
ray structure. The Berendsen barostat was used with a relaxation time of 10,000 steps to allow the
simulation box to resize according to the new composition. We used a Langevin thermostat to main-
tain temperature at 298K with a friction constant of 0.1ps 1. The time-step was 1fs for the first
100ps, and 2fs for the remainder of the equilibration. The non-bonded cutoff was 11.5 A˚.
After equilibration, each system was simulated for 100ns in the canonical ensemble. To accelerate
the simulations, the non-bonded cutoff was set to 9 A˚, the switching function was nonzero at 7.25 A˚,
long-range electrostatics were evaluated at every other simulation step, and hydrogen masses were
increased to 4 a.m.u., which allowed the use of a 4fs time step. For all simulations in which the time-
step was larger than 1fs, covalent bonds to hydrogens were constrained using SHAKE
(Ryckaert et al., 1977). To generate statistics for subsequent fluctuation and covariance analyses,
the equilibration and production simulations were performed five times starting with different initial
velocities.
To ensure that the truncation of the antibody constant regions would not impact the conclusions
of this study, we also simulated by MD the 3BNC60 antibodies without truncation (i.e. including
both the variable and constant regions, for 400ns for each structure. In these simulations, the con-
stant and variable regions remained well-separated (Figure 2—figure supplement 2) suggesting
that the interactions between them were relatively weak. Further, the RMSF fluctuations on the basis
of these simulations were qualitatively unchanged.
Analysis of residue fluctuations
Root mean square residue fluctuations (RMSFs) were used as indicators of protein flexibility. To com-
pute RMSFs for each residue, each antibody system was first coarse-grained (CG) to one bead per
residue. The coordinate for each bead was taken as the center-of-mass (COM) of the residue. The
fluctuation for residue i is computed as
i ¼ r
CG
i   r
CG
i

  2D E12; (2)
where ri
CG is the coordinate triplet of the coarse-grained residue i, and brackets indicate temporal
averaging. The average and standard deviation was computed for each i from the five simulation
repeats. The RMSF calculations were also performed by considering coordinates of the Ca atoms
only. The results are not shown because they were qualitatively similar.
Calculation of conformational entropy
Quasi-harmonic entropies of the CG systems were used as a measure of overall flexibility. Mass-
weighted covariance matrices were computed for each system, as described by (Brooks et al.,
1995), for the HC and LC independently. For each system, the five trajectories were concatenated.
This is permissible because the covariance analysis is not time-dependent. Both classical and quan-
tum entropies were computed using the corresponding harmonic oscillator expressions
(Andricioaei and Karplus, 2001). Only classical entropies are shown because the relative differences
between classical and quantum entropies were similar.
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Affinity maturation model
Data and analysis for the affinity maturation simulations, including the code used to generate all fig-
ures, are available in a GitHub repository (Barton, 2018).
Somatic hypermutation in the dark zone
Then, the AID gene turns on so mutations are introduced with a probability determined by experi-
ments: each B cell of the dark zone divides twice per GC cycle (four divisions per day) (Zhang and
Shakhnovich, 2010) and mutation appears with a probability of 0.20 per sequence per division
(Berek and Milstein, 1987). The mutations affect any amino acids in the variable domains, including
both the CDR and the FWR. Although the FWR constitutes over two thirds of the variable domain by
sequence, mutational hotspots have mostly been found in the CDR (Neuberger and Milstein, 1995;
Tomlinson et al., 1996; Wagner and Neuberger, 1996). Thus, we assume that the probability that
a mutation occurs is higher in the CDR (pCDR = 0.85) than in the framework (pFWR = 0.15).
CDR mutations
CDR mutations can cause a B cell to undergo apoptosis (for example, by making the BCR unable to
fold), be silent (due to redundancy of the genetic code, i.e. synonymous mutation), or modify the
binding energy. The probability that a CDR mutation will follow one of these paths is governed by
probabilities obtained from experiments (Berek and Milstein, 1987). Hence, apoptosis occurs half
of the time, 30% of mutations are silent, and 20% are energy-affecting mutations (Zhang and Shakh-
novich, 2010). Energy-affecting mutations are likely to be deleterious. Experiments have determined
that in protein-protein interactions, between 5% and 10% of the energy-affecting mutations weaken
the binding energy (Moal and Ferna´ndez-Recio, 2012). In our model, the change in binding energy
is sampled from a shifted log-normal distribution whose parameters are chosen to approximate the
empirical distribution of changes in binding energies upon mutation. This distribution is also used to
initialize the binding energies of the founder B cells. We assume that CDR mutations do not affect
flexibility (Q). Thus, the random change in binding energy DE (Ec or Ev, depending on the location of
the CDR mutation) and the initial variable region binding energies are taken to be
DE¼ exp þsrð Þ  o (3)
where r is a standard normal variable with mean zero and standard deviation equal to one. Here o is
a shift parameter, which is needed to center the log-normal distribution properly with respect to
zero, and , s are the mean and standard deviation of the log-normal distribution, respectively.
These parameters are described in Supplementary file 1.
FWR mutations
As described in main text
Selection in the light zone
After SHM, the mutated B cells then migrate to the light zone of the GC, where selection takes plae
through competition for binding to antigens and for receiving T-cell help. B cells with the greatest
binding free energy for the antigen presented on FDCs will have a better chance to internalize that
antigen, break it down into small peptides, and display it on their MHC molecules. These peptide-
MHC (pMHC) complexes can then bind to the cognate receptor of T cells. A productive interaction
results in a survival signal to the B cell through CD40-CD40 ligand signaling. B cells that do not
receive a survival signal die through apoptosis (Foy et al., 1994; Crotty, 2015).
We model the biology with a two-step selection process. First, each B cell successfully internalizes
the antigen it encounters with a probability that grows with the binding free energy and then satu-
rates, following a Langmuir form. The probability that a B cell successfully internalizes an antigen i
that it encounters also depends on the antigen concentration Ci. We assume that this probability fol-
lows a Langmuir formula:
Pint ¼
Cie
 E
1þCie E
(4)
where E is given in Equation (1). B cells that successfully internalize antigen can then go on to the
second step, while the others die automatically. The B cells that internalize antigen are ranked
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according to their binding energy, a proxy for the concentration of pMHC that they display to T
cells, and only the best performers are selected.
Equation 1 in the main text and the discussion that follows therein describes our model for the
effects of CDR and FWR mutations on the binding free energy for antibody binding to variant
antigens.
Recycling to the dark zone, exit for differentiation, and termination of
the GC reaction
As described in main text.
Example: Affinity maturation against a single antigen
Our model depends on several parameters. Some of these are known a priori, e.g. SHM rate and
fate of CDR mutations. Others represent biological quantities which have not yet been measured
experimentally; for these we can make reasonable guesses. The rest do not have direct biological
meaning, and exist on account of the simplified nature of the model. All parameters were adjusted
manually until a good fit to experimental data in the single antigen case was obtained; see Fig-
ure 4—figure supplement 1. Consistent with the qualitative nature of the model, we did not
attempt to choose an ‘optimal’ set of parameters, for example by precisely fitting the typical number
of mutations or GC duration in the single antigen case. A strength of our model is that the qualita-
tive results are robust to some variation in the parameters.
The dynamics of the GC population depends on the overall probabilities that B cells will survive
somatic hypermutation and selection, successfully compete for T cell help, and be recycled back into
the GC. The survival and selection probabilities depend implicitly on mutation rates, fractions of
lethal versus silent and affinity-affecting mutations, etc. These overall probabilities are more impor-
tant to the qualitative shape of the GC dynamics than the precise values of the underlying parame-
ters. We write phelp (help_cutoff in the simulation code) as the proportion of successful B cells which
are selected (i.e. those that receive T cell help). precycle denotes the proportion of B cells which are
recycled back into the GC. The probability that a B cell successfully internalizes an antigen i that it
encounters depends is given by Equation 4 above.
For convenience, all free energies entering into the AM simulations and those shown in the fig-
ures are made nondimensional using kBT. The growth rate of the GC is proportional to the product
psurv  pint  phelpprecycle, where psurv is the probability that a B cell survives somatic hypermutation
without lethal or strongly deleterious mutations.
We roughly tuned these parameters (within known experimental constraints) so that the popula-
tion experiences a sharp decline at the beginning of AM until a few beneficial mutations appear and
allow survival of a few B cells. Then the population plateaus for about 20 days until enough good
mutations accumulate to increase the binding energy dramatically. The population then rises quickly
until it reaches 1,536 cells by around 60 days. Experimental studies of affinity maturation in the pres-
ence of a single antigen showed that the antibodies produced accumulate about 10 mutations and
their binding affinity – which is exponentially proportional to the binding energy (A = exp( E/kBT)) –
increases 1,000-fold (Tas et al., 2016). With our chosen parameters, our model reproduces these
features well (Figure 4—figure supplement 1).
Breadth calculations
Every B cell divides twice per cycle and its daughter cells have only a small chance of generating a
non-lethal mutation. Consequently, the GC contains sets of functionally identical B cells, called B cell
clones. All cells of a clone have the same binding energies and rigidity. The size of a clone varies
with time and depends on its properties as explained above. We use the clone with the largest num-
ber of cells at the end of the reaction as the representative to analyze the events that shaped the
final characteristics of most of the antibodies generated by AM. In order to analyze the breadth, we
compute the binding free energy of this largest clone against an artificial panel of 100 antigens dif-
ferent from those that the antibody matured against. Here we take the overlap parameter l and the
binding strength with the conserved region to be the same as in the simulations, but the binding
strength with the variable region is randomly selected for each new antigen in the panel. Here, the
random binding strength is chosen from a log-normal distribution that is broader (standard deviation
s = 1) and shifted toward weaker binding (mean m = 3) compared to the one used to generate the
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binding free energies for the founder B cell-Ab combinations. This choice is based on the assump-
tion that variable regions for a broad cross-section of antigens should be more variable and less
likely to bind strongly to the Ab than those encountered in the original host. As a proxy for breadth,
we compute the median binding energy of each antibody over the maturation pathway with panel
antigens (Figure 4).
Robustness to variation in l
The value of the overlap parameter we have used in the main text, l = 0.9, is chosen to roughly rep-
resent a swarm of diversified but still highly similar antigens that B cells may encounter in a chroni-
cally infected individual. We tested the robustness of our model to changes in l by performing
simulations identical to those described above, but with l = 0.8, and with a smaller number of panel
antigens (5) to prevent excessive frustration. We also tuned the antigen concentration in simulations
to compare overall, qualitative patterns of Ab maturation at comparable survival rates. We find that
the same qualitative maturation pathways are also observed in these simulations (Figure 4—figure
supplement 2). However, due to the greater dissimilarity between antigens against which the Abs
mature, there is stronger selection for flexibility (lower Q).
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